These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 28223233)

  • 1. Unravelling the pharmacologic opportunities and future directions for targeted therapies in gastro-intestinal cancers Part 1: GI carcinomas.
    Neuzillet C; Rousseau B; Kocher H; Bourget P; Tournigand C
    Pharmacol Ther; 2017 Jun; 174():145-172. PubMed ID: 28223233
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Unravelling the pharmacologic opportunities and future directions for targeted therapies in gastro-intestinal cancers part 2: Neuroendocrine tumours, hepatocellular carcinoma, and gastro-intestinal stromal tumours.
    Neuzillet C; de Mestier L; Rousseau B; Mir O; Hebbar M; Kocher HM; Ruszniewski P; Tournigand C
    Pharmacol Ther; 2018 Jan; 181():49-75. PubMed ID: 28723416
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current and future therapies for targeting HER2 mutations in gastrointestinal cancer.
    El Dika I; Ilson DH
    Expert Rev Anticancer Ther; 2018 Nov; 18(11):1085-1092. PubMed ID: 30092682
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changing pathology with changing drugs: tumors of the gastrointestinal tract.
    Cervera P; Fléjou JF
    Pathobiology; 2011; 78(2):76-89. PubMed ID: 21677471
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ramucirumab for the treatment of gastric cancers, colorectal adenocarcinomas, and other gastrointestinal malignancies.
    Aprile G; Ferrari L; Cremolini C; Bergamo F; Fontanella C; Battaglin F; Rihawi K; Lonardi S; Loupakis F; Scartozzi M
    Expert Rev Clin Pharmacol; 2016 Jul; 9(7):877-85. PubMed ID: 27149032
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictive factors to targeted treatment in gastrointestinal carcinomas.
    Silvestris N; Marech I; Brunetti AE; Azzariti A; Numico G; Cicero G; Delcuratolo S; De Luca R; Burz C; Lorusso V
    Cancer Biomark; 2014; 14(2-3):151-62. PubMed ID: 24878816
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epidermal growth factor receptor: pathway, therapies, and pipeline.
    Goffin JR; Zbuk K
    Clin Ther; 2013 Sep; 35(9):1282-303. PubMed ID: 24054705
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Checkpoint inhibitors in gastrointestinal cancers: Expectations and reality.
    Kourie HR; Tabchi S; Ghosn M
    World J Gastroenterol; 2017 May; 23(17):3017-3021. PubMed ID: 28533658
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting HER 2 and angiogenesis in gastric cancer.
    Jomrich G; Schoppmann SF
    Expert Rev Anticancer Ther; 2016; 16(1):111-22. PubMed ID: 26567753
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monoclonal antibodies in gastrointestinal cancers.
    Bronte G; Cicero G; Cusenza S; Galvano A; Musso E; Rizzo S; Sortino G; Roselli M; Bazan V; Fiorentino E; Russo A
    Expert Opin Biol Ther; 2013 Jun; 13(6):889-900. PubMed ID: 23441760
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sustained Inhibition of HER3 and EGFR Is Necessary to Induce Regression of HER2-Amplified Gastrointestinal Carcinomas.
    Leto SM; Sassi F; Catalano I; Torri V; Migliardi G; Zanella ER; Throsby M; Bertotti A; Trusolino L
    Clin Cancer Res; 2015 Dec; 21(24):5519-31. PubMed ID: 26296355
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The RAS paradox of the EGFR-targeted therapy in colorectal cancer].
    Tímár J; Láng I
    Magy Onkol; 2008 Jun; 52(2):185-91. PubMed ID: 18640895
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New advances in targeted therapies for squamous cell carcinoma of the head and neck.
    Machiels JP; Schmitz S
    Anticancer Drugs; 2011 Aug; 22(7):626-33. PubMed ID: 21048493
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune Checkpoint Inhibitors in the Treatment of Gastrointestinal Malignancies: A Review of Current and Future Therapies.
    Hsu A; Mendelson L; Almhanna K
    R I Med J (2013); 2020 Apr; 103(3):33-37. PubMed ID: 32236159
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular-targeted therapies in the treatment of squamous cell carcinomas of the head and neck.
    Le Tourneau C; Siu LL
    Curr Opin Oncol; 2008 May; 20(3):256-63. PubMed ID: 18391623
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overcoming Resistance to Targeted Therapies in Gastrointestinal Cancers: Progress to Date and Progress to Come.
    Chen C; Di Bartolomeo M; Corallo S; Strickler JH; Goyal L
    Am Soc Clin Oncol Educ Book; 2020 May; 40():161-173. PubMed ID: 32421451
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Old Tyrosine Kinase Inhibitors and Newcomers in Gastrointestinal Cancer Treatment.
    Giordani E; Zoratto F; Strudel M; Papa A; Rossi L; Minozzi M; Caruso D; Zaccarelli E; Verrico M; Tomao S
    Curr Cancer Drug Targets; 2016; 16(2):175-85. PubMed ID: 26278713
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimizing outcomes in HER2-positive breast cancer: the molecular rationale.
    Esteva FJ; Pusztai L
    Oncology (Williston Park); 2005 Nov; 19(13 Suppl 5):5-16. PubMed ID: 19364051
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictive and prognostic factors in the complex treatment of patients with colorectal cancer.
    László L
    Magy Onkol; 2010 Dec; 54(4):383-94. PubMed ID: 21163770
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aquaporins: Their role in gastrointestinal malignancies.
    Nagaraju GP; Basha R; Rajitha B; Alese OB; Alam A; Pattnaik S; El-Rayes B
    Cancer Lett; 2016 Apr; 373(1):12-18. PubMed ID: 26780474
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.